Agnieszka Pawlak

Prof. Dr. Agnieszka Pawlak


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in JACC: Heart Failure
Verified
Journal Article
Closed access
MCMarco Canepa
Marco Canepa
CFCandida Fonseca
Candida Fonseca
OCOvidiu Chioncel
Ovidiu Chioncel
CLCécile Laroche
Cécile Laroche
MCMaria G. Crespo-Leiro
Maria G. Crespo-Leiro
HGH. Gunes
H. Gunes

8 January 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Grzegorz KopecGrzegorz Kopec
Grzegorz Kopec
Marcin Kurzyna, MD, PhD, FESCMarcin Kurzyna, MD, PhD, FESC
Marcin Kurzyna, MD, PhD, FESC
EMEwa Mroczek
Ewa Mroczek
ŁCŁukasz Chrzanowski
Łukasz Chrzanowski
TMTatiana Mularek-Kubzdela
Tatiana Mularek-Kubzdela
Adam TorbickiAdam Torbicki
Adam Torbicki
Current knowledge of pulmonary arterial hypertension (PAH) epidemiology is based mainly on data from Western populations, and therefore we aimed to characterize a large group of Caucasian PAH adults of Central-Eastern European origin. We analyzed data of incident and prevalent PAH adults enrolled in a prospective national registry involving all Polish PAH centers. The estimated prevalence and annual incidence of PAH were 30.8/mln adults and 5.2/mln adults, respectively and they were the highest in females ≥65 years old. The most frequent type of PAH was idiopathic (n = 444; 46%) followed by PAH associated with congenital heart diseases (CHD-PAH, n = 356; 36.7%), and PAH associated with connective tissue disease (CTD-PAH, n = 132; 13.6%). At enrollment, most incident cases (71.9%) were at intermediate mortality risk and the prevalent cases had most of their risk factors in the intermediate or high risk range. The use of triple combination therapy was rare (4.7%). A high prevalence of PAH among older population confirms the changing demographics of PAH found in the Western countries. In contrast, we found: a female predominance across all age groups, a high proportion of patients with CHD-PAH as compared to patients with CTD-PAH and a low use of triple combination therapy.

16 November 2021 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
JKJacek Kubica
Jacek Kubica
MOMałgorzata Ostrowska
Małgorzata Ostrowska
WSWioleta Stolarek
Wioleta Stolarek
MKMichal Kasprzak
Michal Kasprzak
KGKlaudyna Grzelakowska
Klaudyna Grzelakowska
JKJarosław Kaźmierczak
Jarosław Kaźmierczak
Aims The coronavirus disease-2019 (COVID-19) pandemic has changed the landscape of medical care delivery worldwide. We aimed to assess the influence of COVID-19 pandemic on hospital admissions and in-hospital mortality rate in patients with acute heart failure (AHF) in a retrospective, multicentre study. Methods and results From 1 January 2019 to 31 December 2020, a total of 101 433 patients were hospitalized in 24 Cardiology Departments in Poland. The number of patients admitted due to AHF decreased by 23.4% from 9853 in 2019 to 7546 in 2020 (P < 0.001). We noted a significant reduction of self-referrals in the times of COVID-19 pandemic accounting 27.8% (P < 0.001), with increased number of AHF patients brought by an ambulance by 15.9% (P < 0.001). The length of hospital stay was overall similar (7.7 ± 2.8 vs. 8.2 ± 3.7 days; P = not significant). The in-hospital all-cause mortality in AHF patients was 444 (5.2%) in 2019 vs. 406 (6.5%) in 2020 (P < 0.001). A total number of AHF patients with concomitant COVID-19 was 239 (3.2% of AHF patients hospitalized in 2020). The rate of in-hospital deaths in AHF patients with COVID-19 was extremely high accounting 31.4%, reaching up to 44.1% in the peak of the pandemic in November 2020. Conclusions Our study indicates that the COVID-19 pandemic led to (i) reduced hospital admissions for AHF; (ii) decreased number of self-referred AHF patients and increased number of AHF patients brought by an ambulance; and (iii) increased in-hospital mortality for AHF with very high mortality rate for concomitant AHF and COVID-19.

1 March 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
Paweł RubiśPaweł Rubiś
Paweł Rubiś
JTJustyna Totoń-Żurańska
Justyna Totoń-Żurańska
SWSylwia Wiśniowska-Śmiałek
Sylwia Wiśniowska-Śmiałek
KHKatarzyna Holcman
Katarzyna Holcman
MKMaria Kołton-Wróż
Maria Kołton-Wróż
PPPiotr Podolec
Piotr Podolec

31 January 2012 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
APAgnieszka Pawlak
Agnieszka Pawlak
RGRobert Julian Gil
Robert Julian Gil
TKT. Kulawik
T. Kulawik
MPM. Pronicki
M. Pronicki
AKAgnieszka Karkucinska-Wieckowska
Agnieszka Karkucinska-Wieckowska
ECE. Czarnowska
E. Czarnowska
: Pawlak A, Gil RJ, Kulawik T, Pronicki M, Karkucińska‐Więckowska A, Szymańska‐Dębińska T, Gil K, Lagwinski N, Czarnowska E (Central Clinical Hospital of Ministry of Internal Affairs and Administration, Warsaw; Mossakowski Medical Research Centre, Academy of Science, Warsaw; The Children’s Memorial Health Institute, Warsaw, Poland; and Community Medical Centers, Fresno, CA, USA). Type of desmin expression in cardiomyocytes – a good marker of heart failure development in idiopathic dilated cardiomyopathy. J Intern Med 2012; 272: 287–297.Aim.  The aim of this study was to determine whether remodelling of the desmin (DES) cytoskeleton affects myocardial function and whether it could be a useful marker of disease progression in patients with idiopathic dilated cardiomyopathy (IDCM).Material and methods.  Endomyocardial biopsy was performed in 195 IDCM patients, and five to six specimens were collected from the left ventricle. DES expression was evaluated using tissue immunostaining and Western blotting. The study population was assigned to four groups according to DES expression type: I, normal DES staining at Z‐lines giving a regular pattern of cross‐striation (n = 57); IIA, increased DES staining with a regular pattern of cross‐striation (n = 40); IIB, increased DES staining with an irregular pattern of cross‐striation and/or the presence of aggregates (n = 56); and III, decreased/lack of DES staining (n = 42). Fibrosis, cardiomyocyte hypertrophy and ultrastructure were assessed for the four types of DES expression.Results.  The pathological types of DES expression (IIB or III) were associated with pathological changes in mitochondria and the contractile apparatus. Cardiomyocyte diameter and level of fibrosis were both significantly affected. DES expression type correlated with NYHA class, left ventricular end‐diastolic diameter, left ventricular ejection fraction and the level of N‐terminal pro‐brain natriuretic protein.Conclusion.  The type of immunohistochemical DES expression correlated with the level of myocardial injury at the cellular and organ levels. This correlation was similar to that observed between DES expression and the well‐established biochemical, echocardiographic and clinical parameters of heart failure (HF). DES expression type could be used as an important diagnostic feature of HF development.

1 September 2016 in Advances in Medical Sciences
Verified
Journal Article
Closed access
KGKatarzyna E. Gil
Katarzyna E. Gil
APAgnieszka Pawlak
Agnieszka Pawlak
RGRobert Julian Gil
Robert Julian Gil
MFMałgorzata Frontczak-Baniewicz
Małgorzata Frontczak-Baniewicz
JBJacek Bil
Jacek Bil